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Agents Promoting Cellular Differentiation 
  
 
 
 In general, cells that are less differentiated have a greater tendency to proliferation.  This is most clearly 
seen with embryonal, and especially stem cells.  As cells mature, they become more differentiated into specific 
cell types, with a consequent significant decrease in proliferative ability.  Cancer cells tend to regress to a less 
differentiated phenotype.  Those that are the least differentiated tend to be show greater aggressive malignant 
properties.  This is evident in the pathological description of cancer cells, often described on a range of well 
differentiated to poorly differentiated or anaplastic. These processes of differentiation are largely under genetic 
control. 
 
 Various natural substances such as retinoids and different forms of Vitamin D, as well as numerous 
medications, including agents typically used for other illnesses, such as the glitazones for diabetes and fibrates 
for lipid abnormalities effect different nuclear receptors, which have the effect of stimulating genes which 
promote cellular differentiation.  Retinoids stimulate retinoid receptors (RAR and RXR), certain classes of 
Vitamin D  stimulate vitamin D receptors (VDR), and glitazones and fibrates stimulates peroxisome 
proliferation activation receptors (PPAR).  There is often an interaction, and synergism between these different 
substances and their receptors. This is particularly important because there is dose limiting toxicity for these 
agents, such as hypercalcemia for Vitamin D and liver toxicity for Vitamin A.  These toxicities have greatly 
limited their clinical usefulness when employed as single agents. Their potential synergism between themselves 
(1,2,3 4), synergism with some conventional chemotherapy agents (5) as well as other natural substances (6), 
raises the hope that they could be given in non toxic dosages and be of benefit in an integrative treatment 
program. 
 
Synergism 
 
 A general principal in integrative cancer treatment is that most agents have more than one clinical action 
and effect, and these effects are often linked to each other.  Vitamin D, as a cogent example, has the ability to 
(a) induce differentiation, (b) induce apoptosis, (c) induce the activity of the tumor suppressors  p21 or p27, (d) 
inhibit angiogenesis,  and (e) inhibit cell migration (7). Retinoids show similar effects, as well as having a 
reciprocal inhibitory relationship with NFkB, a cancer promoting transcription factor (8). These actions are 
linked, as for example, p21, as a tumor suppressor gene, induces apoptosis.  Another important principle in 
integrative cancer treatment is that single agents, though likely to show only slight activity when used alone, 
display synergistic and more comprehensive effects when used together with other agents.  This principle is also 
understood and used in conventional cancer treatment, as most chemotherapy regimens employ multiple agents 
with different modes of action.  This synergism also allows lower doses of single agents and limits toxicity.  
This is especially highlighted in discussing differentiation inducing vitamins, as they have potential toxicity 
when used in higher doses. 
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Retinoids 
 
 Retinoids such as the forms found in food and supplements (retinyl ester such as retinyl palmitate), 9 
and 13 cis retinoic acid, as well as pharmacological forms such as all trans retinoic acid (ATRA), exert their 
effect by effecting the transcription of a variety of genes critical to cellular proliferation and differentiation.  
Retinoids are transported to the cellular nucleus, where they effect the retinoic acid receptors, RAR and RXR.  
These receptors also have the effect of increasing the DNA binding affinity to other receptors such as the 
Vitamin D receptor, and PPAR (peroxisome proliferator activated receptor). (9). These actions have the effect 
of promoting cellular differentiation and decreasing proliferation. They have also been shown to promote 
apoptosis and cell cycle arrest through degradation and decreased formation of stimulatory proteins.  These 
actions involve the proteosome/ubiquitin pathway (10), a pathway of great interest because of, among other 
things, its central role in the production of NFkB, a transcription factor which promotes cellular proliferation, 
and is central in chemotherapy resistance.  
 
 Retinoids have been studied in various malignancies, and have significant efficacy in acute 
promyelocytic leukemia, and leukoplakia, a premalignant condition.  They have been shown to effect a very 
wide range of cells, such as breast (11). A number of experimental and clinical studies have been performed in 
the past two decades with retinoids showing that they inhibit or reverse the carcinogenic process in some 
organs, including hematological malignancies as well as premalignant and malignant lesions in the oral cavity, 
head and neck, breast, skin and liver (12). Despite these encouraging findings, the clinical use of retinoids, as a 
single agent, has been relatively disappointing. Goodman completed a phase II trial of oral retinol (200,000 
units/m2) in 65 patients with advanced cancer, with only minimal success.  Six of sixty five patients showed a 
limited response (13). Pastorino treated patients with curatively resected stage 1 lung cancer with Vitamin A, 
300,000 iu for twelve months, observing for the occurrence of second malignancies in this group of patients 
with a significant smoking history.  There was some decrease noted after 46 months (14). Lippmann published a 
similar study, however using a synthetic retinoid, isoretinoin, and found no difference in the development of 
second malignancies (15). As different agents were used, it’s difficult to draw a firm conclusion about the 
ability of vitamin A alone to prevent recurrent or second malignancies in this group of patients.   
 
 As opposed to the use of a single agent, most integrative oncology regimens would use vitamin A in 
combination with other agents, taking advantage of the synergistic effect.  In this context, numerous studies 
have shown synergistic benefit.  Koga showed breast cancer cells treated with vitamin A had a synergistic 
benefit when cotreated with vitamin D and/or antiestrogens (2). Konopleva showed an enhanced differentiation 
and proapoptotic effect on leukemic cells when vitamin A analogues were combined with PPAR agonists (16). 
A combination of interferon alpha and isoretinoin was shown to be of benefit to patients with refractory 
hematological malignancies (17). 
 
 Issues related to vitamin A toxicity are of importance.  Acute vitamin A toxicity is rare, and requires 
extremely high doses, usually over 500,000 iu.  There is significant toxicity in pregnant women and children, 
and high doses should be avoided in these populations.  Chronic vitamin A toxicity is documented to occur with 
prolonged dosing of as low as 25,000 iu/day, but most authors quote > 50,000 iu/day for periods of a year or 
more. Early signs of toxicity include anorexia, headache, blurred vision, loss of hair, bleeding lips, cracking and 
peeling skin, muscular stiffness and pain (18).  Liver enzymes and retinol levels should be followed periodically 
in patients on moderate to high doses. It is also known that very prolonged uses of 5-10,000 iu/day predisposes 
to the development of osteoporosis.  These issues need to be considered in the light of the specific oncological 
clinical situation.  For instance, in patients with progressive malignancies, uses of 50,000 iu/day for up to a year 
can be considered, along with a comprehensive treatment program.  It is also possible, that the use of lower 
doses, when combined with other differentiating agents like vitamin D, can give similar beneficial effects as 
higher doses of vitamin A used alone. 
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Vitamin D 
 
 Vitamin D has generally been considered in relation to bone and mineral metabolism. Vitamin D has 
numerous other actions. Deficiencies have been associated with an increased prevalence of hypertension and 
multiple sclerosis.  In the realm of oncology, lower serum levels of vitamin D  have been associated with an 
increased incidence of various malignancies, including breast (19), colorectal (20), prostate and pancreas (21). 
Vitamin D has numerous physiologic actions which can be important in the treatment of malignancies, 
including “an increase in G0/G1 arrest, induction of apoptosis and differentiation, and modulation of expression 
of growth factor receptors” (22), as well as important effects on cell differentiation. It has also been shown to 
stabilize DNA in a murine lymphoma model, leading to a decrease in mutations as well as increased survival 
(23). 
 An in vitro study with numerous differentiating agents, including two forms of vitamin D, showed an 
inhibition of  proliferation on head and neck tumor cells (4). Gross, et al. (24) studied patients with early stage 
prostate cancer, who received calcitriol  (1-25 OH vitamin D) after initial surgery or radiation therapy. They 
found a significantly decreased rate of PSA rise.  Dosages ranged from 0.5 to 2.5 mcg/day, depending on the 
calcium levels obtained during treatment. Beer et al. (5), have performed a series of studies using high oral 
doses of calcitriol given weekly to patients with prostate and other cancers, in an attempt to avoid the potential 
hypercalcemia that can occur with daily doses. They began with low doses, and escalated doses as tolerated, 
finding that the optimal dose was .5mcg/kg/week. This allowed the peak 1-25OH vitamin D levels to exceed 
1ng/ml, which, from in vitro studies, has been felt to be necessary to show a clinical effect. They also report on 
a phase 2 study in patients with androgen unresponsive prostate cancer, who were treated with a combination of 
Taxol and weekly high dose calcitriol. This showed improved responses regarding PSA and tumor shrinkage 
compared to historical controls with Taxol alone (5). Another study, however, found unimpressive results when 
calcitriol was combined with zoledronate and dexamethasone in progressive prostate cancer patients (25). 
However, in this study, calcitriol was given at much lower daily oral doses than the weekly schedule studied by 
Beer. Trouillas (26) studied 11 patients with aggressive brain tumors (10 with glioblastoma multiforme and 1 
with anaplastic astrocytoma) who were treated in a phase II trial involving surgery or biopsy, radiotherapy (64 
Gy), chemotherapy with VM26-CCNU or  fotemustine, and alfacalcidol ( a synthetic Vit D analogue which is a 
precursor to calcitriol) at the daily dose of 0.04 mcg/kg. Three of the 11 patients were long-term survivors (still 
alive after 7,5 and 4 years). 
 
Due to the concern of hypercalcemia, attempts to circumvent this adverse reaction have also included 
the development and use of vitamin D analogues (26,27,28), with mixed effects so far.  Other dosing schedules, 
such as the weekly schedule discussed above, are being studied.  A comprehensive article discussing optimal 
dosing, optimal blood levels, and controversies regarding toxicity should be consulted (29). In this review, 
Vieth presents data suggesting that usual recommendations for dosages and serum levels are much lower than 
optimal. He suggests that a normal blood level of vitamin D is greater than 100 mmol/liter , as opposed to the 
typical stated ranges of 20-80.  He also states that toxic states have not been documented until the blood level is 
>200. (Note that vitamin D levels are also often reported as ng/ml.  200 mmol/l is about equivalent of 
85ng/ml).He also states that daily intake of vitamin D3 of 4000 iu/day is safe.  This is significantly higher than 
the usual recommended doses of 400-800 iu/day. 
 
In addition to dosage changes, synergism has been noted with numerous other agents, including 
retinoids, genistein (6), vitamin E (30), curcumin and NSAIDS (31).  
 
As discussed above under synergism, the use of these differentiating agents in combination has the 
potential to improve efficacy, while at the same time limiting the potential for adverse effects.  
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Peroxisome Proliferator Activated Receptor Agonists (PPAR agonists) 
 
 PPARs are nuclear receptors closely connected with the RAR, RXR and vitamin D receptors discussed 
above.  Stimulation of the vitamin A receptors can have a reciprocal stimulatory effect on the vitamin D 
receptor and PPARs.  The PPAR of most interest is PPAR gamma.  
 
 Various substances act as ligands for PPAR gamma, combining with it and leading to signal 
transduction and gene stimulation.  They include, of great interest, the glitazone family of medications, 
commonly used in diabetic patients to increase insulin sensitivity. Other agonists include long chain fatty acids 
and eicosanoids.  Many agents, including NSAIDS and COX 2 inhibitors have the effect of stimulating PPARs. 
 
 PPAR agonists have been shown to have numerous relevant clinical effects besides differentiation, 
including inhibition of NFkB, proapoptotic, antiproliferative, and antiangiogenetic actions (32). 
 
 PPAR agonists have been studied in a wide range of tumor types, including carcinomas (33), 
lymphomas (34,35), and sarcomas (36). Patients with medium to high grade liposarcomas, where the state of 
differentiation is of great importance, were treated with troglitazone, and an improved state of tumor 
differentiation was noted. 
 
Practical Aspects of Differentiation Therapy 
 
 As with most integrative treatment regimens, multiagent protocols are usually employed.  There are 
numerous rational reasons to employ multiagent protocols in the attempt to promote differentiation in malignant 
cells.  Nature itself suggests that this should be done, as the three nuclear receptor groups discussed above, are 
in close anatomic proximation, and stimulation of one group has reciprocal effects on the other groups, through 
the process of dimerization. 
 
 Issues of toxicity, especially with the fat soluble vitamins A and D are important considerations.  The 
dosages of vitamin A are likely to be very dependent on the time of the course of treatment.  With extended 
treatment courses, clinical and laboratory monitoring is of importance.  Vitamin D is usually given in doses far 
below the optimal range.  Nevertheless, high doses, and the calcitriol form particularly, can induce 
hypercalcemia.  Various treatment regimens, using different forms of natural vitamin D (such as D3 available 
OTC, and calcitriol;1-25 OH Vit D, which is available only by prescription), and vitamin D synthetic analogues, 
as well as different treatment schedules, including once weekly doses, are actively being studied. The forms 
used, and dosages prescribed could depend on the clinical stage and treatment goal.  For instance, patients in a 
relatively stable, wait and see stage could be treated with 25-OH regimens as described below.  The two clinical 
studies using Vit D for patients in a more progressive stage, in association with active conventional treatment 
(prostate cancer and brain gliomas), used 1-25 OH forms (calcitriol for prostate cancer and a calcitriol 
precursor, alfacalcidol, for brain gliomas). Levels of calcium and Vitamin D should be monitored at frequent 
intervals.  It should be noted that most laboratories report normal ranges of Vitamin D which are probably 
significantly lower than the optimal levels.  One should aim for a range of 50-100 ng/ml, or 100-180 mmol/liter.  
The use of PPAR agonists involves at present mainly prescription medications primarily used for diabetics, the 
glitazones. 
 
 In addition to the synergistic effects noted between these three groups of agents, numerous other 
substances, including antioxidants and anti-inflammatory agents, have been shown to increase the benefits. 
Therefore the use of differentiation agents should be combined with the general integrative treatment protocol 
outlined elsewhere. 
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 Dosage recommendations, with the above mentioned considerations and precautions are as follows: 
 
 A) Vitamin A – retinol levels and liver enzymes should be followed 
       Short term use – 100,000-300,000 iu/day, not to exceed 1-2 months 
        Medium term use – 40,000-50,000 iu/day, for up to 1 year 
       Long term use – 20,000 iu/d, for up to 5 years 
 
B) Vitamin D – 25-OH levels, and serum Calcium levels should be followed and doses adjusted          
      accordingly 
      Vit D2:   50,000 i.u. po  weekly for 6-8 weeks and reevaluate 
       Vit D3:   1,000 – 6,000 iu/day 
                  Calcitriol (1-25OH vit D):   .5mcg/kg weekly (used in clinical trial for treatment of prostate   
                                 cancer.  A precursor, alfacalcidol, was used as an active treatment for brain gliomas.   
 
 C) PPAR agonists 
      Consider the use of glitazones, with appropriate blood sugar monitoring. 
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